Results Healthcare advises Duke Street on its acquisition of Kent Pharmaceuticals

  • Service: M&A
  • Sector: Healthcare
  • Sub Sector: Pharma & Biotech
  • Engagement Type: Buy Side
Jun 2019
has acquired

Results Healthcare is delighted to have been the exclusive financial advisor to Duke Street on its acquisition of Kent Pharmaceuticals. This transaction reinforces our expertise in driving value for private equity clients in the life sciences sector.

Duke Street, the leading European midmarket private equity group, has agreed to acquire Kent Pharmaceuticals and Athlone Laboratories (Kent), manufacturers and distributors of specialist off-patent/generic pharmaceuticals with locations in both the UK and Ireland. Kent is currently owned by DCC Vital.

Kent is a UK market leader in several niche products in the large, growing and non-cyclical market for generic pharmaceuticals, selling primarily to the hospital and pharmacy wholesaler channels. Its portfolio of products is diversified across multiple therapeutic areas, with particular strengths in analgesics, anti-infectives and penicillins. Kent portfolio contains mainly niche, value-added products, which are complex to manufacture. A strong pipeline of new product development opportunities has already been put in place by the management. Athlone Laboratories is a leading European manufacturer of specialist beta-lactam antibiotics based in Ireland.

Duke Street is backing a strong management team at Kent, led by Chief Executive Debashis Dasgupta, who joined DCC Vital two years ago, bringing strong international experience in the Pharmaceutical Industry with previous senior leadership positions in Sanofi and Ranbaxy. Debashis and his leadership team have developed a compelling growth proposition for Kent & Athlone, which aligns with Duke Street’s vision for the opportunities presented in the sector. Duke Street’s strategy will focus on new product development and expansion into other selected branded generic markets across the EMEA region, building further on the highly diversified and scaled specialist generics business it is today. Kevin James, an experienced generics CEO/Chairman, will contribute a strong combination of skills and experience as non-Executive Chairman.

We are very pleased to acquire Kent, a market-leading business that we believe represents a significant opportunity for Duke Street and our investors.

Charlie Troup

Managing Partner at Duke Street

Sector Related Deals

May 2022
A subsidiary of Servier
has divested its anti-LAG-3 monoclonal antibody to
A subsidiary of Sino Biopharmaceutical Limited
Mar 2022
has divested its Ringaskiddy, Ireland, manufacturing facility
Mar 2022
has divested its Boucherville, Canada manufacturing facility
Jan 2022
has divested its API manufacturing site in Cramlington, UK, to
Nov 2021
has invested in
company name confidential
Jun 2021
has acquired a drug product manufacturing facility from
May 2021
has formed a strategic alliance with
Mar 2021
has licensed the patents and know-how to its Crystalomics Formulation Technology to
Jan 2021
has divested its Mirabel manufacturing site in Riom, France to